{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:53:21Z","timestamp":1765558401047,"version":"3.48.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-28763-3","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:42:13Z","timestamp":1765557733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic liver disease and cirrhosis mortality following surgery for colon or rectal cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Lai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"28763_CR1","first-page":"3461","volume":"11","author":"TW Mudd","year":"2021","unstructured":"Mudd, T. W. & Guddati, A. K. Management of hepatotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res. 11, 3461\u20133474 (2021).","journal-title":"Am. J. Cancer Res."},{"key":"28763_CR2","doi-asserted-by":"publisher","first-page":"e069794","DOI":"10.1136\/bmjopen-2022-069794","volume":"13","author":"J Han","year":"2023","unstructured":"Han, J. et al. Risk factors for irinotecan-induced liver injury: a retrospective multicentre cross-sectional study in China. BMJ open. 13, e069794. https:\/\/doi.org\/10.1136\/bmjopen-2022-069794 (2023).","journal-title":"BMJ open."},{"key":"28763_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/jcph.2059","volume":"62","author":"J Li","year":"2022","unstructured":"Li, J. et al. Drug-Drug interactions and disease status are associated with Irinotecan-Induced hepatotoxicity: A Cross-Sectional study in Shanghai. J. Clin. Pharmacol. 62, 1160\u20131169. https:\/\/doi.org\/10.1002\/jcph.2059 (2022).","journal-title":"J. Clin. Pharmacol."},{"key":"28763_CR4","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.aohep.2019.11.012","volume":"19","author":"L Meunier","year":"2020","unstructured":"Meunier, L. & Larrey, D. Chemotherapy-associated steatohepatitis. Ann. Hepatol. 19, 597\u2013601. https:\/\/doi.org\/10.1016\/j.aohep.2019.11.012 (2020).","journal-title":"Ann. Hepatol."},{"key":"28763_CR5","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/c8dt00838h","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun, R., Moussa,, Y. E. & Wheate, N. J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 47, 6645\u20136653. https:\/\/doi.org\/10.1039\/c8dt00838h (2018).","journal-title":"Dalton Trans."},{"key":"28763_CR6","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.ejso.2017.05.008","volume":"43","author":"G Duwe","year":"2017","unstructured":"Duwe, G. et al. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Eur. J. Surg. Oncology: J. Eur. Soc. Surg. Oncol. Br. Association Surg. Oncol. 43, 1668\u20131681. https:\/\/doi.org\/10.1016\/j.ejso.2017.05.008 (2017).","journal-title":"Eur. J. Surg. Oncology: J. Eur. Soc. Surg. Oncol. Br. Association Surg. Oncol."},{"key":"28763_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","volume":"15","author":"JJ Jennings","year":"2019","unstructured":"Jennings, J. J., Mandaliya, R., Nakshabandi, A. & Lewis, J. H. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin. Drug Metab. Toxicol. 15, 231\u2013244. https:\/\/doi.org\/10.1080\/17425255.2019.1574744 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"28763_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-030-02505-2_8","volume":"995","author":"Y Tian","year":"2018","unstructured":"Tian, Y., Abu-Sbeih, H. & Wang, Y. Immune checkpoint Inhibitors-Induced hepatitis. Adv. Exp. Med. Biol. 995, 159\u2013164. https:\/\/doi.org\/10.1007\/978-3-030-02505-2_8 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"28763_CR9","doi-asserted-by":"publisher","first-page":"e000042","DOI":"10.1136\/esmoopen-2016-000042","volume":"1","author":"M Pinter","year":"2016","unstructured":"Pinter, M., Trauner, M., Peck-Radosavljevic, M. & Sieghart, W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO open. 1, e000042. https:\/\/doi.org\/10.1136\/esmoopen-2016-000042 (2016).","journal-title":"ESMO open."},{"key":"28763_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.currproblcancer.2012.03.007","volume":"36","author":"HS Park","year":"2012","unstructured":"Park, H. S., Lloyd, S., Decker, R. H., Wilson, L. D. & Yu, J. B. Overview of the Surveillance, Epidemiology, and end results database: evolution, data variables, and quality assurance. Curr. Probl. Cancer. 36, 183\u2013190. https:\/\/doi.org\/10.1016\/j.currproblcancer.2012.03.007 (2012).","journal-title":"Curr. Probl. Cancer"},{"key":"28763_CR11","doi-asserted-by":"publisher","unstructured":"Guo, Y. et al. Causes of death after prostate cancer diagnosis: A Population-Based study. Oxidative Med. Cell. Longev. 2022 (8145173). https:\/\/doi.org\/10.1155\/2022\/8145173 (2022).","DOI":"10.1155\/2022\/8145173"},{"key":"28763_CR12","doi-asserted-by":"publisher","first-page":"e20289","DOI":"10.7759\/cureus.20289","volume":"13","author":"RU Harvitkar","year":"2021","unstructured":"Harvitkar, R. U. et al. Non-Cancer causes of death in patients with pancreatic adenocarcinoma: A Surveillance, Epidemiology, and end results (SEER)-Based study. Cureus 13, e20289. https:\/\/doi.org\/10.7759\/cureus.20289 (2021).","journal-title":"Cureus"},{"key":"28763_CR13","doi-asserted-by":"publisher","unstructured":"Zhai, M. et al. Short-term mortality risks among patients with non-metastatic bladder cancer. BMC Cancer. 20 https:\/\/doi.org\/10.1186\/s12885-020-07655-x (2020).","DOI":"10.1186\/s12885-020-07655-x"},{"key":"28763_CR14","first-page":"735","volume":"66","author":"AD Lin","year":"2003","unstructured":"Lin, A. D. et al. Antiandrogen-associated hepatotoxicity in the management of advanced prostate cancer. J. Chin. Med. Association: JCMA. 66, 735\u2013740 (2003).","journal-title":"J. Chin. Med. Association: JCMA"},{"key":"28763_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/01480545.2018.1504957","volume":"43","author":"WAQ Hailan","year":"2020","unstructured":"Hailan, W. A. Q. et al. Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice. Drug Chem. Toxicol. 43, 158\u2013164. https:\/\/doi.org\/10.1080\/01480545.2018.1504957 (2020).","journal-title":"Drug Chem. Toxicol."},{"key":"28763_CR16","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bjc.2014.579","volume":"112","author":"V Bagnardi","year":"2015","unstructured":"Bagnardi, V. et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br. J. Cancer. 112, 580\u2013593. https:\/\/doi.org\/10.1038\/bjc.2014.579 (2015).","journal-title":"Br. J. Cancer"},{"key":"28763_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/jamainternmed.2016.1548","volume":"176","author":"SC Moore","year":"2016","unstructured":"Moore, S. C. et al. Association of Leisure-Time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern. Med. 176, 816\u2013825. https:\/\/doi.org\/10.1001\/jamainternmed.2016.1548 (2016).","journal-title":"JAMA Intern. Med."},{"key":"28763_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.rgmxen.2023.12.001","volume":"89","author":"JA Velarde-Ruiz Velasco","year":"2024","unstructured":"Velarde-Ruiz Velasco, J. A. et al. Immune-mediated hepatitis: basic concepts and treatment. Revista De Gastroenterol. De Mexico (English). 89, 106\u2013120. https:\/\/doi.org\/10.1016\/j.rgmxen.2023.12.001 (2024).","journal-title":"Revista De Gastroenterol. De Mexico (English)"},{"key":"28763_CR19","doi-asserted-by":"publisher","first-page":"1077468","DOI":"10.3389\/fphar.2022.1077468","volume":"13","author":"Z Liu","year":"2022","unstructured":"Liu, Z., Zhu, Y., Xie, H. & Zou, Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives. Front. Pharmacol. 13, 1077468. https:\/\/doi.org\/10.3389\/fphar.2022.1077468 (2022).","journal-title":"Front. Pharmacol."},{"key":"28763_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group. J. Immunother. Cancer. 5, 95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z (2017).","journal-title":"J. Immunother. Cancer"},{"key":"28763_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659\u2013670. https:\/\/doi.org\/10.1016\/s1470-2045(22)00197-8 (2022).","journal-title":"Lancet Oncol."},{"key":"28763_CR22","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.14218\/jcth.2022.00105","volume":"10","author":"T Da Cunha","year":"2022","unstructured":"Da Cunha, T., Wu, G. Y. & Vaziri, H. Immunotherapy-induced hepatotoxicity: A review. J. Clin. Transl Hepatol. 10, 1194\u20131204. https:\/\/doi.org\/10.14218\/jcth.2022.00105 (2022).","journal-title":"J. Clin. Transl Hepatol."},{"key":"28763_CR23","first-page":"147","volume":"49","author":"KD Bertakis","year":"2000","unstructured":"Bertakis, K. D., Azari, R., Helms, L. J., Callahan, E. J. & Robbins, J. A. Gender differences in the utilization of health care services. J. Fam. Pract. 49, 147\u2013152 (2000).","journal-title":"J. Fam. Pract."},{"key":"28763_CR24","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","volume":"42","author":"MR DiMatteo","year":"2004","unstructured":"DiMatteo, M. R. Variations in patients\u2019 adherence to medical recommendations: a quantitative review of 50 years of research. Med. Care. 42, 200\u2013209. https:\/\/doi.org\/10.1097\/01.mlr.0000114908.90348.f9 (2004).","journal-title":"Med. Care"},{"key":"28763_CR25","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.jhepr.2023.100870","volume":"5","author":"KM Cooper","year":"2023","unstructured":"Cooper, K. M., Delk, M., Devuni, D. & Sarkar, M. Sex differences in chronic liver disease and benign liver lesions. JHEP Reports: Innov. Hepatol. 5, 100870. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100870 (2023).","journal-title":"JHEP Reports: Innov. Hepatol."},{"key":"28763_CR26","doi-asserted-by":"publisher","unstructured":"Licata, A. et al. Impact of sex and gender on clinical management of patients with advanced chronic liver disease and type 2 diabetes. J. Personalized Med. 13 https:\/\/doi.org\/10.3390\/jpm13030558 (2023).","DOI":"10.3390\/jpm13030558"},{"key":"28763_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.03.017","author":"T Guan","year":"2024","unstructured":"Guan, T. et al. Long-term and short-term cardiovascular disease mortality among patients of 21 non-metastatic cancers. J. Adv. Res. https:\/\/doi.org\/10.1016\/j.jare.2024.03.017 (2024).","journal-title":"J. Adv. Res."},{"key":"28763_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13181-021-00833-8","volume":"17","author":"N Chhabra","year":"2021","unstructured":"Chhabra, N. & Kennedy, J. A. Review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J. Med. Toxicology: Official J. Am. Coll. Med. Toxicol. 17, 411\u2013424. https:\/\/doi.org\/10.1007\/s13181-021-00833-8 (2021).","journal-title":"J. Med. Toxicology: Official J. Am. Coll. Med. Toxicol."},{"key":"28763_CR29","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/cncr.34375","volume":"128","author":"Z Lu","year":"2022","unstructured":"Lu, Z. et al. Long-term risk of cardiovascular disease mortality among classic hodgkin lymphoma survivors. Cancer 128, 3330\u20133339. https:\/\/doi.org\/10.1002\/cncr.34375 (2022).","journal-title":"Cancer"},{"key":"28763_CR30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1741-7015-9-70","volume":"9","author":"V Nobili","year":"2011","unstructured":"Nobili, V., Carter-Kent, C. & Feldstein, A. E. The role of lifestyle changes in the management of chronic liver disease. BMC Med. 9, 70. https:\/\/doi.org\/10.1186\/1741-7015-9-70 (2011).","journal-title":"BMC Med."},{"key":"28763_CR31","doi-asserted-by":"publisher","first-page":"100564","DOI":"10.1016\/j.lanwpc.2022.100564","volume":"28","author":"Y Pang","year":"2022","unstructured":"Pang, Y. et al. The role of lifestyle factors on comorbidity of chronic liver disease and cardiometabolic disease in Chinese population: A prospective cohort study. Lancet Reg. Health Western Pac. 28, 100564. https:\/\/doi.org\/10.1016\/j.lanwpc.2022.100564 (2022).","journal-title":"Lancet Reg. Health Western Pac."},{"key":"28763_CR32","doi-asserted-by":"publisher","first-page":"100263","DOI":"10.1016\/j.jhepr.2021.100263","volume":"3","author":"CV Schneider","year":"2021","unstructured":"Schneider, C. V., Zandvakili, I., Thaiss, C. A. & Schneider, K. M. Physical activity is associated with reduced risk of liver disease in the prospective UK biobank cohort. JHEP Reports: Innov. Hepatol. 3, 100263. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100263 (2021).","journal-title":"JHEP Reports: Innov. Hepatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28763-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28763-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:42:13Z","timestamp":1765557733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28763-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28763"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28763-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This article does not contain any studies with animals performed by any of the authors. Due to the anonymous processing of data within the SEER database, institutional review board approval was unnecessary. The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical statement"}}],"article-number":"43736"}}